Table 5.
Number of systemic or severe adverse events following vaccination in SARS-CoV-2 previously exposed subjects. .
| β | e β | 95% CI | p-value | |
|---|---|---|---|---|
| Intercept | 0.45 | 1.57 | 0.66-3.71 | 0.297 |
| Age | -0.01 | 0.98 | 0.96-0.99 | 0.013 |
| Sex (M) | -1.00 | 0.36 | 0.25-0.51 | <0.001 |
| Body Mass Index | 0.004 | 1.00 | 0.97-1.03 | 0.776 |
| Delta IgG | 0.10 | 1.10 | 1.05-1.16 | <0.001 |
| mRNA-1273 | 0.23 | 1.26 | 0.48-3.31 | 0.628 |
| Gam-COVID-Vac | 1.27 | 3.57 | 1.07-11.89 | 0.038 |
| Coronavac | -1.13 | 0.32 | 0.18-0.57 | <0.001 |
| ChAdOx1-S | -0.18 | 0.82 | 0.40-1.67 | 0.597 |
| Delta IgG*mRNA-1273 | -0.001 | 0.99 | 0.86-1.15 | 0.982 |
| Delta IgG*Gam-COVID-Vac | -8.57 | 0.0001 | 0.00016-0.00022 | <0.001 |
| Delta IgG*Coronavac | 0.19 | 1.22 | 0.52-2.84 | 0.644 |
| Delta IgG*ChAdOx1-S | -1.23 | 0.28 | 0.10-0.76 | 0.013 |
Poisson Generalized Linear Model regression. Reference group is BNT162b2 mRNA. Women and young individuals developed more severe or systemic AEFI (AEs). There was no effect of Body Mass Index. In subjects previously exposed to SARS-CoV-2, those receiving Gam-COVID-Vac showed a greater number of AEs compared to BNT162b mRNA, while subjects receiving Coronavac showed significantly fewer events when compared to BNT162b mRNA.* means "interaction", i.e. the product of the variables.